Acacia Pharma braces for approval of potential blockbuster post-op nausea drug
- UK-based Acacia's ADP421 is in late-stage development for the treatment of post-operative nausea and vomiting (PONV), a common complication of surgery.
- Phase III results showed that ADP421 reduced the risk of PONV by 19.4%.
- ADP421 is a dopamine antagonist antiemetic that provides an alternative to other treatments for PONV, which mainly consist of 5HT3s and corticosteroids.
Despite routine use of approved anti-emetics, many patients continue to suffer from PONV. While other drugs in the same class as ADP421 have shown significant side effects associated with heart rhythm disturbances and movement disorders, three phase III studies of ADP421 have demonstrated a higher level of safety, making ADP421 a potentially ideal medication to become the mainstay of treatment for PONV.